C3 and psoriasis: Previously, we have found that the percentage of mast cells expressing C3c immunoreactivity is increased in the lesional skin of patients with psoriasis or basal cell carcinoma, and mast cells were suggested to be a marked source for C3 degradation products, including iC3b.